Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-12-01T09:07:12.773Z Has data issue: false hasContentIssue false

Psychiatric symptoms’ treatment to patients addicted to alcohol, cocaine and crack

Published online by Cambridge University Press:  16 April 2020

A.M. Silva
Affiliation:
Cardiology, São Paulo, Brazil
M.L. Pequeno
Affiliation:
Albert Einstein Hospital, São Paulo, Brazil
M.D. Feltrin
Affiliation:
Albert Einstein Hospital, São Paulo, Brazil
J.A. Gonçalves
Affiliation:
Albert Einstein Hospital, São Paulo, Brazil
F.J. Ropero Pelaez
Affiliation:
Mathematical Computation and Cognition, Universidade Federal do ABC, Santo André, Brazil
J. Vitorino
Affiliation:
Centro Universitário São Camilo, São Paulo, Brazil
S.F. Taniguchi
Affiliation:
Albert Einstein Hospital, São Paulo, Brazil Centro Universitário São Camilo, São Paulo, Brazil

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Extrapyramidal side-effects (EPS) related to the use of neuroleptics are an limiting factor to patients’ compliance during the treatment with this group of drugs.

Objective

The aim of this study was to identify which drugs are mostly prescribed for cocaine, crack and alcohol addicts’ psychotic symptoms.

Methods

This study selected 31 patients with mean age of 33.61 ± 1.90 enrolled with psychotic disorders related to use of illicit drugs in an public mental health service.

Results

Patients under this study were addict to alcohol (61,29%), cocaine or crack, associated (38,71%).

The percentage of patients addicted to alcohol treated with typical neuroleptic-(typical-neurol) was 42,11%, with atypical neuroleptic-(atypical-neurol) was 26,32%, with association of typical and atypical neuroleptics-(typical/atypical-neurol) (21,60%), and with benzodiazepines associated with serotonin-reuptake-inhibitors (BZD-SSRI) (10,00)%. The cocaine or crack associated or not with alcohol patients were treated with typical-neurol (41,67%), atypical-neurol (41,67%), typical/atypical-neurolol (8,33%) and BZD-SSRI (8,33%).

The EPS related to the use of neuroleptics in patients addicted to alcohol were given biperiden (52,65%), promethazine or anticolvulsant (Prometh/Anticonv) (42,11%) and no-treatment (5,26%). For those patients, addicted to cocaine, crack and alcohol altogether were given biperiden (58,34%), Prometh/Anticonv (25,00%) and no-treatment (16,67%).

Conclusions

In the case of using neuroleptics, the EPS should be reversed with biperiden in an dose combined with the neuroleptic prescribed to each individual, in an effort to minimized hallucination. Also, if sedation was indicated using Prometh/Anticonv to patients that are taking neuroleptics, then the health care professional team in charge must be aware of consciousness level-reduction.

Type
P01-112
Copyright
Copyright © European Psychiatric Association 2011
Submit a response

Comments

No Comments have been published for this article.